Nanobiotix S.A. — Investor Relations & Filings

Nanobiotix S.A. is a late-stage clinical biotechnology company that pioneers the development of physics-based nanotherapeutics. The company's lead candidate, NBTXR3, is a potential first-in-class radioenhancer designed to be injected directly into a tumor. It works by amplifying the dose of radiotherapy absorbed by cancer cells without increasing the dose in surrounding healthy tissues. This localized destruction also aims to prime an immune response to attack metastatic tumors. Nanobiotix is engaged in a global licensing agreement with Janssen Pharmaceutica NV, a Johnson & Johnson company, for the co-development and commercialization of NBTXR3. The initial development focus is on solid tumors, particularly in head, neck, and lung cancers, for patient populations with limited treatment options.